These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 23696633)

  • 41. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.
    Burgos-Vargas R; Loyola-Sanchez A; Ramiro S; Reding-Bernal A; Alvarez-Hernandez E; van der Heijde D; Vázquez-Mellado J
    Arthritis Res Ther; 2022 Aug; 24(1):187. PubMed ID: 35941676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis.
    Gossec L; van der Heijde D; Melian A; Krupa DA; James MK; Cavanaugh PF; Reicin AS; Dougados M
    Ann Rheum Dis; 2005 Nov; 64(11):1563-7. PubMed ID: 15731291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
    Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
    Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
    Baeten D; Østergaard M; Wei JC; Sieper J; Järvinen P; Tam LS; Salvarani C; Kim TH; Solinger A; Datsenko Y; Pamulapati C; Visvanathan S; Hall DB; Aslanyan S; Scholl P; Padula SJ
    Ann Rheum Dis; 2018 Sep; 77(9):1295-1302. PubMed ID: 29945918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials.
    Sieper J; Porter-Brown B; Thompson L; Harari O; Dougados M
    Ann Rheum Dis; 2014 Jan; 73(1):95-100. PubMed ID: 23765873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cross-sectional study on clinical characteristics of Saudi axial spondylarthritis: preliminary results.
    Bedaiwi MK; AlRasheed RF; Bin Zuair A; Alqurtas EM; Baeshen MO; Omair MA
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5241-5247. PubMed ID: 34486699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
    Nazeri S; Jamshidi AR; Mahmoudi M; Vojdanian M; Khadem Azarian S; Afraei S; Mostafaei S; Hosseini M; Mirshafiey A
    Pharmacol Rep; 2019 Jun; 71(3):393-398. PubMed ID: 31003148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
    Sieper J; Braun J; Kay J; Badalamenti S; Radin AR; Jiao L; Fiore S; Momtahen T; Yancopoulos GD; Stahl N; Inman RD
    Ann Rheum Dis; 2015 Jun; 74(6):1051-7. PubMed ID: 24550171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
    van der Heijde D; Baraf HS; Ramos-Remus C; Calin A; Weaver AL; Schiff M; James M; Markind JE; Reicin AS; Melian A; Dougados M
    Arthritis Rheum; 2005 Apr; 52(4):1205-15. PubMed ID: 15818702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
    Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicenter, open-label, long-term study of three-year infliximab administration in Japanese patients with ankylosing spondylitis.
    Kobayashi S; Yoshinari T
    Mod Rheumatol; 2017 Jan; 27(1):142-149. PubMed ID: 27299733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
    Mease P; Sieper J; Van den Bosch F; Rahman P; Karunaratne PM; Pangan AL
    Arthritis Rheumatol; 2015 Apr; 67(4):914-23. PubMed ID: 25545240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
    Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis.
    Dougados M; Simon P; Braun J; Burgos-Vargas R; Maksymowych WP; Sieper J; van der Heijde D
    Ann Rheum Dis; 2011 Feb; 70(2):249-51. PubMed ID: 20829199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.